| 摘要 |
The present invention provides a method of inhibiting connective tissue degradation that comprises administering to a patient having a condition in which connective tissue is degraded a therapeutically effective amount of a compound having the formulawhere R1, R2, R3, and R4 are independently hydrogen, hydroxy, halo, amino, nitro, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, CF3, CN, S(O)n-,R6 and R7 are independently hydrogen, C1-C6 alkyl, or acyl;n is 0 to 2;R8 is hydrogen or C1-C6 alkyl;W is S or O;Z is C1-C6 alkyl, C1-C6 alkoxy, or NR9R10;R9 and R10 are independently hydrogen or C1-C6 alkyl; andR5 iswhere Y is hydroxy, thiol, amino, or NHCN;X is sulfur or oxygen; and Q is sulfur, oxygen, NH, or NCN, and the pharmaceutically acceptable salts and prodrugs thereof. Also provided is a method of inhibiting the production of matrix metalloproteinases comprising administering to a patient having a condition associated with matrix metalloproteinase-mediated tissue degradation a therapeutically effective amount of a compound having the formulawhere R1, R2, R3, and R4 are independently hydrogen, hydroxy, halo, amino, nitro, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, CF3, CN, S(O)n-,R6 and R7 are independently hydrogen, C1-C6 alkyl or acyl;n is 0 to 2;R8 is hydrogen or C1-C6 alkyl;W is S or O;Z is C1-C6 alkyl, C1-C6 alkoxy, or NR9R10;R9 and R10 are independently hydrogen or C1-C6 alkyl; andR5 iswhere Y is hydroxy, thiol, amino, or NHCN;X is sulfur or oxygen; and Q is sulfur, oxygen, NH, or NCN, and the pharmaceutically acceptable salts and prodrugs thereof.
|
